{
    "id": "8749cf61-2e35-473a-bfe5-49d342a17ff3",
    "code": {
        "code": "34391-3",
        "codeSystem": "2.16.840.1.113883.6.1",
        "displayName": "HUMAN PRESCRIPTION DRUG LABEL"
    },
    "name": "ENDOMETRIN",
    "organization": "Ferring Pharmaceuticals Inc.",
    "effectiveTime": "20250327",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "ADIPIC ACID",
            "code": "76A0JE0FKJ"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "PROGESTERONE",
            "code": "4G7DS2Q64Y"
        }
    ],
    "indications": "1 usage endometrin 速 ( progesterone ) indicated support embryo implantation early pregnancy supplementation corpus luteal function part assisted reproductive technology ( art ) treatment program infertile women. endometrin 速 progesterone indicated support embryo implantation early pregnancy supplementation corpus luteal function part assisted reproductive technology ( art ) treatment program infertile women. ( 1 )",
    "contraindications": "4 endometrin contraindicated individuals following conditions: previous allergic progesterone ingredients endometrin [ ] description ( 11 ) undiagnosed vaginal bleeding known missed abortion ectopic pregnancy liver disease known suspected malignancy breast genital organs active arterial venous thromboembolism severe thrombophlebitis, history events previous allergic progesterone ingredients endometrin vaginal insert ( 4 ) undiagnosed vaginal bleeding ( 4 ) known missed abortion ectopic pregnancy ( 4 ) liver disease ( 4 ) known suspected malignancy breast genital organs ( 4 ) active arterial venous thromboembolism severe thrombophlebitis, history events ( 4 )",
    "warningsAndPrecautions": "5 life-threatening arterial venous thromboembolic disorders may occur hormone treatment, including treatment endometrin. discontinue endometrin suspected. ( 5.1 ) observe patients history depression closely. consider discontinuation symptoms worsen. ( 5.2 ) endometrin recommended vaginal products ( antifungal products ) may alter progesterone release absorption vaginal insert. ( 5.3 ) 5.1 cardiovascular cerebrovascular disorders physician alert earliest signs myocardial infarction, cerebrovascular disorders, arterial venous thromboembolism ( venous thromboembolism pulmonary embolism ) , thrombophlebitis, retinal thrombosis. endometrin discontinued suspected. 5.2 depression patients history depression need closely observed. consider discontinuation symptoms worsen. 5.3 vaginal products endometrin recommended vaginal products ( antifungal products ) may alter progesterone release absorption vaginal insert [ ] . ( 7 )",
    "adverseReactions": "6 common reported ( greater 2% ) post-oocyte retrieval pain, abdominal pain, nausea, ovarian hyperstimulation syndrome. ( 6 ) leaflet summarizes important information endometrin. report suspected reactions, contact ferring pharmaceuticals inc. 1-888-ferring ( 1-888-337-7464 ) fda 1-800-fda-1088 www.fda.gov/medwatch. 6.1 experience trials conducted widely varying conditions, reaction rates observed trials cannot directly compared rates trials another may reflect rates observed practice. safety data reflect exposure endometrin 808 infertile women ( 74.9% white, 10.3% hispanic, 5.4% black, 5% asian, 4.6% ) single assisted reproductive technology 10 week study conducted u.s. endometrin studied doses 100 mg twice daily 100 mg three times daily. occurred rate greater equal 2% either endometrin group summarized table 1. table 1: number frequency reported women treated endometrin assisted reproductive technology study body system endometrin 100 mg twice daily ( n=404 ) endometrin 100 mg three times daily ( n=404 ) preferred term gastrointestinal disorders abdominal pain 50 ( 12% ) 50 ( 12% ) nausea 32 ( 8% ) 29 ( 7% ) abdominal distension 18 ( 4% ) 17 ( 4% ) constipation 9 ( 2% ) 14 ( 3% ) vomiting 13 ( 3% ) 9 ( 2% ) general disorders site conditions fatigue 7 ( 2% ) 12 ( 3% ) infections infestations urinary tract infection 9 ( 2% ) 4 ( 1% ) injury, poisoning procedural complications post-oocyte retrieval pain 115 ( 28% ) 102 ( 25% ) nervous system disorders headache 15 ( 4% ) 13 ( 3% ) reproductive system breast disorders ovarian hyperstimulation syndrome 30 ( 7% ) 27 ( 7% ) uterine spasm 15 ( 4% ) 11 ( 3% ) vaginal bleeding 13 ( 3% ) 14 ( 3% ) less common reported included vaginal irritation, itching, burning, discomfort, urticaria, peripheral edema. 6.2 expected reaction profile seen progesterone endometrin also expected similar drugs containing progesterone may include breast tenderness, bloating, mood swings, irritability, drowsiness.",
    "indications_original": "1 INDICATIONS AND USAGE ENDOMETRIN 速 (progesterone) is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women. ENDOMETRIN 速 is a progesterone indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women. ( 1 )",
    "contraindications_original": "4 CONTRAINDICATIONS ENDOMETRIN is contraindicated in individuals with any of the following conditions: Previous allergic reactions to progesterone or any of the ingredients of ENDOMETRIN [ see ] Description (11) Undiagnosed vaginal bleeding Known missed abortion or ectopic pregnancy Liver disease Known or suspected malignancy of the breast or genital organs Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events Previous allergic reactions to progesterone or any of the ingredients of ENDOMETRIN Vaginal Insert ( 4 ) Undiagnosed vaginal bleeding ( 4 ) Known missed abortion or ectopic pregnancy ( 4 ) Liver disease ( 4 ) Known or suspected malignancy of the breast or genital organs ( 4 ) Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events ( 4 )",
    "warningsAndPrecautions_original": "5 WARNINGS AND PRECAUTIONS Life-threatening arterial or venous thromboembolic disorders may occur during hormone treatment, including treatment with ENDOMETRIN. Discontinue ENDOMETRIN if any of these are suspected. ( 5.1 ) Observe patients with a history of depression closely. Consider discontinuation if symptoms worsen. ( 5.2 ) ENDOMETRIN is not recommended for use with other vaginal products (such as antifungal products) as this may alter progesterone release and absorption from the vaginal insert. ( 5.3 ) 5.1\tCardiovascular or Cerebrovascular Disorders The physician should be alert to earliest signs of myocardial infarction, cerebrovascular disorders, arterial or venous thromboembolism (venous thromboembolism or pulmonary embolism), thrombophlebitis, or retinal thrombosis. ENDOMETRIN should be discontinued if any of these are suspected. 5.2\tDepression Patients with a history of depression need to be closely observed. Consider discontinuation if symptoms worsen. 5.3 Use of Other Vaginal Products ENDOMETRIN should not be recommended for use with other vaginal products (such as antifungal products) as this may alter progesterone release and absorption from the vaginal insert [ see ]. Drug Interactions (7)",
    "adverseReactions_original": "6 ADVERSE REACTIONS The most common adverse reactions reported (greater than 2%) were post-oocyte retrieval pain, abdominal pain, nausea, and ovarian hyperstimulation syndrome. ( 6 ) This leaflet summarizes the most important information about ENDOMETRIN. To report SUSPECTED ADVERSE REACTIONS, contact Ferring Pharmaceuticals Inc. at 1-888-FERRING (1-888-337-7464) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1\tClinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data reflect exposure to ENDOMETRIN in 808 infertile women (74.9% White, 10.3% Hispanic, 5.4% Black, 5% Asian, and 4.6% Other) in a single Assisted Reproductive Technology 10 week clinical study conducted in the U.S. ENDOMETRIN was studied at doses of 100 mg twice daily and 100 mg three times daily. The adverse reactions that occurred at a rate greater than or equal to 2% in either ENDOMETRIN group are summarized in Table 1. Table 1: Number and Frequency of Reported Adverse Reactions in Women Treated with ENDOMETRIN in an Assisted Reproductive Technology Study Body System ENDOMETRIN 100 mg twice daily (N=404) ENDOMETRIN 100 mg three times daily (N=404) Preferred Term Gastrointestinal Disorders Abdominal pain 50 (12%) 50 (12%) Nausea 32 (8%) 29 (7%) Abdominal distension 18 (4%) 17 (4%) Constipation 9 (2%) 14 (3%) Vomiting 13 (3%) 9 (2%) General Disorders and Administration Site Conditions Fatigue 7 (2%) 12 (3%) Infections and Infestations Urinary tract infection 9 (2%) 4 (1%) Injury, Poisoning and Procedural Complications Post-oocyte retrieval pain 115 (28%) 102 (25%) Nervous System Disorders Headache 15 (4%) 13 (3%) Reproductive System and Breast Disorders Ovarian hyperstimulation syndrome 30 (7%) 27 (7%) Uterine spasm 15 (4%) 11 (3%) Vaginal bleeding 13 (3%) 14 (3%) Other less common reported adverse reactions included vaginal irritation, itching, burning, discomfort, urticaria, and peripheral edema. 6.2\tExpected Adverse Reaction Profile Seen with Progesterone ENDOMETRIN is also expected to have adverse reactions similar to other drugs containing progesterone that may include breast tenderness, bloating, mood swings, irritability, and drowsiness."
}